Paradigm Biopharmaceuticals Ltd has released a press release.
Phase 3 Protocol Submission to US FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Paradigm Investor Update
- PAR receives positive response from US FDA for phase 3
- Appendix 4E and 2024 Annual Report
- Type D Response Submitted and Received by the US FDA
- Half Yearly Report and Accounts
Later from Paradigm Biopharmaceuticals
- 2024 Chairman Address and AGM Presentation
- Response to ASX Price Query
- Paradigm to Proceed with Phase 3 Knee OA Trial
- Trading Halt
- Successful Completion of $16M Placement for Phase 3
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals